Product
ELVN-002
2 clinical trials
8 indications
Indication
Breast Cancer (HER2-positive)Indication
HER2-positive Gastric CancerIndication
HER2-positive solid tumorsIndication
ERBB2 AmplificationIndication
Colorectal CancerIndication
HER2 Mutant Non-small Cell Lung CancerIndication
Breast CancerIndication
HER2 gene mutationClinical trial
A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast CancerStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-07-01